DGAP-News: Defence Therapeutics Inc.
/ Key word(s): Miscellaneous
Defence Therapeutics Inc.: DEFENCE THERAPEUTICS RECEIVES U.S. PATENT COVERING ITS ADC PLATFORM TECHNOLOGY
The issuer is solely responsible for the content of this announcement.
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE THERAPEUTICS RECEIVES U.S. PATENT COVERING ITS ADC PLATFORM TECHNOLOGY
Vancouver, BC, Canada, August 8th, 2022 – Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate (“ADC”), is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted Defence Therapeutics Inc. the U.S. patent no. 11,352,437.
This new patent covers conjugated compounds permitting delivery of antibodies to the nucleus through the Company proprietary technology AccumTM. AccumTM is the first solution for precision delivery method for improved intracellular antibody drug conjugate (“ADC”) routing. Overcoming problematic cell recycling and rejection patterns, Accum™ enables ADCs to control intracellular delivery of chemotherapeutic drugs, resulting in superior preclinical anti-tumor activity. By increasing the tumor targeting specificity – due to increased drug accumulation – non-specific toxicity in healthy cells is greatly reduced.
“This US patent is an important milestone in protecting the commercial potential of AccumTM directly related to our ADC program. Defence is expecting key ADC in vivo results in a few weeks from independent ADCs studies ongoing in Europe. Defence’s commitment to protect the innovation is crucial as its ADC development and ADC interest applied in oncology is advancing rapidly”, says Mr. Plouffe, the CEO of Defence Therapeutics.
According to Precedence Research Predicts, the global oncology market size is expected to worth around US$ 536.01 billion by 2029 from valued at USD 286.04 billion in 2021 and growing at a CAGR of 8.2% from 2021 to 2030. Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Rising concern about the cancer and patient is one of the major factors driving the market for oncology market.
The global antibody drug conjugates market size is expected to reach over USD 22.87 billion by 2030, registering a CAGR of 16.4% during the forecast period, according to a recent 2022 report by Grand View Research Inc. The presence of strong pipeline products and strategic initiatives undertaken by the key players are expected to drive the market growth during the forecast period.
Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Cautionary Statement Regarding “Forward-Looking” Information
This release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||Defence Therapeutics Inc.|
|1680 – 200 Burrard St|
|Listed:||Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto|
|EQS News ID:||1413875|
|End of News||DGAP News Service|